8-K: Aquestive Therapeutics Anaphylm Study Results Boost NDA Resubmission Hopes

Aquestive Therapeutics announced positive topline results from human factors and pharmacokinetic studies for its Anaphylm sublingual film, supporting a planned New Drug Application resubmission to the FDA.

Summary

• Aquestive Therapeutics has announced positive topline results from human factors (HF) validation and pharmacokinetic (PK) studies for its Anaphylm (dibutepinephrine) sublingual film.
• These studies were conducted to support the planned resubmission of the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the treatment of Type 1 allergic reactions, including anaphylaxis.
• The revised packaging design and instructions for use significantly improved ease of use, reducing median time to open the pouch from 17 seconds to 3 seconds.
• Incorrect film placement decreased by over 80% in the new HF study compared to the previous one.
• Self-administration PK results were comparable to clinician-administered PK results, with a geometric mean Cmax of 391.7 pg/mL and median Tmax of 12 minutes.
• Even with purposeful top-of-tongue placement, the PK study showed a geometric mean Cmax above 100 pg/mL and clinically meaningful pharmacodynamic (PD) results.
• The company plans to resubmit the Anaphylm NDA in the third quarter of 2026, less than eight months after receiving a Complete Response Letter (CRL) in January 2026.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive development, indicating significant progress in addressing FDA concerns and moving closer to potential market approval for Anaphylm.

Positives

• Significant improvements in human factors study results, addressing all deficiencies identified by the FDA in the January 2026 CRL.
• Reduced median time to open the pouch from 17 seconds to 3 seconds.
• Substantial decrease in incorrect film placement (over 80% reduction).
• No observed chewing or removal of the film in the latest HF study.
• Self-administration PK results are comparable to clinician-administered results.
• Top-of-tongue administration, while incorrect, still yielded a geometric mean Cmax above 100 pg/mL and clinically meaningful PD response.
• The company is on track to resubmit the NDA in the third quarter of 2026.
• Anaphylm has the potential to be the first and only non-invasive, orally delivered epinephrine product.

Negatives

• The FDA previously issued a Complete Response Letter (CRL) in January 2026, indicating issues with pouch opening, film tearing, incorrect placement, chewing, and removal.
• Despite improvements, 2 out of 105 participants in the HF study still had incorrect film placement.
• Top-of-tongue placement, though yielding some positive PD, resulted in a significantly lower geometric mean Cmax (112.7 pg/mL) compared to correct sublingual placement (391.7 pg/mL).

Risks

• The FDA may disagree with the company's interpretation of study results or findings.
• The FDA may request additional information, analyses, or studies.
• Delays in the regulatory approval process.
• The risk that the company may be unable to successfully address all matters identified by the FDA in the Complete Response Letter.
• Potential for differing FDA review timelines than expected.
• Risks associated with obtaining regulatory approvals outside the United States.
• The final approved labeling, packaging, and instructions for use remain subject to FDA review and approval.

Future Outlook

Aquestive Therapeutics plans to resubmit its New Drug Application (NDA) for Anaphylm in the third quarter of 2026. The company is also advancing regulatory submissions for Anaphylm in Canada, the UK, and the European Union.

Management Comments

• "Our Anaphylm program has reached an important milestone. The topline results from our human factors and pharmacokinetic studies reinforce our confidence in the revised packaging design and instructions for use as we prepare for our planned NDA resubmission."
• "If approved, we believe Anaphylm has the potential to be the first and only non-invasive, orally delivered epinephrine product for patients at risk of life-threatening allergic reactions."
• "For patients who are at risk of having a severe allergic reaction, having a package for your epinephrine thats easy to open in an emergency can make all the difference. In our topline analysis, patients and caregivers were better able to use the revised packaging, and our pharmacokinetic data met the endpoints we set out to achieve."
• "Even if used incorrectly, such as placing on top of the tongue instead of under the tongue, the pharmacodynamic response is what you would want in an epinephrine product during an allergic reaction. I am excited to see continued innovation in this critical treatment area. Increasing options for patients is vital to improving outcomes in the real world."

Industry Context

StockSavvy.ai notes that the development of Anaphylm addresses a significant unmet need for convenient and accessible epinephrine delivery for anaphylaxis, a life-threatening condition. The focus on human factors and pharmacokinetic studies highlights the critical role of usability and predictable drug absorption in gaining FDA approval for such emergency treatments.

Stakeholder Impact

• Shareholders: Positive impact expected from progress towards potential market approval of a key product, which could lead to future revenue growth.
• Patients: Potential for a more convenient and accessible treatment option for life-threatening allergic reactions.
• Healthcare Providers: Introduction of a novel delivery method for epinephrine that may improve patient compliance and emergency response.
• FDA: The company is actively working to satisfy the FDA's requirements for approval.

Next Steps

• Resubmit the Anaphylm New Drug Application (NDA) to the FDA in the third quarter of 2026.
• Advance regulatory submissions for Anaphylm in Canada, the UK, and the European Union.
• Continue to address any further FDA requests or requirements related to the Anaphylm NDA.

Key Dates

Recommendation

The positive study results are a significant step towards potential FDA approval, which is a key catalyst. However, the outcome of the NDA resubmission is still uncertain, and the company faces ongoing regulatory and development risks. Therefore, a 'hold' recommendation is appropriate pending further clarity on FDA review and potential approval.

Keywords

Anaphylm, epinephrine, anaphylaxis, sublingual film, human factors study, pharmacokinetic study, NDA resubmission, FDA